Athira Pharma, Inc. received an amended Schedule 13G reporting updated passive ownership by Acorn-affiliated investment entities and Anders Hove in its common stock.
Acorn Bioventures, L.P. and Acorn Capital Advisors GP, LLC each report beneficial ownership of 250,348 shares, or 2.6% of Athira’s common stock. Acorn Bioventures 2, L.P. and Acorn Capital Advisors GP 2, LLC each report 345,720 shares, or 3.6% of the class. Anders Hove, as manager of both general partners, reports beneficial ownership of 596,068 shares, representing 6.2% of Athira’s common stock.
The percentages are based on 9,604,313 shares outstanding as of November 18, 2025, as cited in an Athira announcement. The filing is certified as a passive investment under the 13G standard, stating the securities are not held for the purpose of changing or influencing control of Athira Pharma.
Positive
None.
Negative
None.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 1)
Athira Pharma, Inc.
(Name of Issuer)
Common Stock, $0.0001 Par Value
(Title of Class of Securities)
04746L104
(CUSIP Number)
01/06/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
SCHEDULE 13G
CUSIP No.
04746L104
1
Names of Reporting Persons
ACORN BIOVENTURES, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
250,348.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
250,348.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
250,348.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
2.6 %
12
Type of Reporting Person (See Instructions)
PN
SCHEDULE 13G
CUSIP No.
04746L104
1
Names of Reporting Persons
ACORN CAPITAL ADVISORS GP, LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
250,348.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
250,348.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
250,348.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
2.6 %
12
Type of Reporting Person (See Instructions)
OO
SCHEDULE 13G
CUSIP No.
04746L104
1
Names of Reporting Persons
ACORN BIOVENTURES 2, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
345,720.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
345,720.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
345,720.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
3.6 %
12
Type of Reporting Person (See Instructions)
PN
SCHEDULE 13G
CUSIP No.
04746L104
1
Names of Reporting Persons
Acorn Capital Advisors GP 2, LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
345,720.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
345,720.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
345,720.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
3.6 %
12
Type of Reporting Person (See Instructions)
OO
SCHEDULE 13G
CUSIP No.
04746L104
1
Names of Reporting Persons
Anders Hove
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
596,068.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
596,068.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
596,068.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
6.2 %
12
Type of Reporting Person (See Instructions)
IN
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Athira Pharma, Inc.
(b)
Address of issuer's principal executive offices:
18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL, WASHINGTON, 98011.
Item 2.
(a)
Name of person filing:
Acorn Bioventures, L.P.
Acorn Capital Advisors GP, LLC
Acorn Bioventures 2, L.P.
Acorn Capital Advisors GP2, LLC
Anders Hove
(b)
Address or principal business office or, if none, residence:
420 Lexington Avenue, Suite 2626, New York, New York 10170
(c)
Citizenship:
Acorn Bioventures, L.P. and Acorn Bioventures 2 L.P. are both Delaware limited partnerships. Acorn Capital Advisors GP, LLC and Acorn Capital Advisors GP 2, LLC are both Delaware limited liability companies. Anders Hove is a citizen of the United States of America.
(d)
Title of class of securities:
Common Stock, $0.0001 Par Value
(e)
CUSIP No.:
04746L104
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
The information required by Items 4(a) - (c) is set forth in Rows (5) - (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each Reporting Person.
(b)
Percent of class:
The percentages set forth herein are calculated based upon 9,604,313 shares of Common Stock outstanding as of November 18, 2025 as reported in the firm's announcement of an exclusive licensing agreement and financing round.
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
Acorn Capital Advisors GP, LLC is the General Partner of Acorn Bioventures, L.P. and may be deemed to beneficially own the shares of Common Stock beneficially owned by Acorn Bioventures, L.P. Acorn Capital Advisors GP 2, LLC is the General Partner of Acorn Bioventures 2, L.P. and may be deemed to beneficially own the shares of Common Stock beneficially owned by Acorn Bioventures 2, L.P.
(ii) Shared power to vote or to direct the vote:
Anders Hove, in his capacity as Manager of each of Acorn Capital Advisors GP, LLC and Acorn Capital Advisors GP 2, LLC, may be deemed to beneficially own the shares beneficially owned by each of Acorn Capital Advisors GP, LLC and Acorn Capital Advisors GP 2, LLC.
(iii) Sole power to dispose or to direct the disposition of:
N/A
(iv) Shared power to dispose or to direct the disposition of:
N/A
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
What ownership stake in Athira Pharma (ATHA) does Anders Hove report?
The filing states that Anders Hove beneficially owns 596,068 shares of Athira Pharma common stock, representing 6.2% of the outstanding shares.
How many Athira Pharma (ATHA) shares do Acorn Bioventures funds report owning?
The filing shows Acorn Bioventures, L.P. and its general partner reporting 250,348 shares (2.6%), and Acorn Bioventures 2, L.P. and its general partner reporting 345,720 shares (3.6%) of Athira common stock.
What is the total Athira Pharma (ATHA) share count used to calculate these ownership percentages?
Percentages are calculated using 9,604,313 shares of Athira Pharma common stock outstanding as of November 18, 2025, as cited in an Athira announcement.
Is the Acorn and Hove ownership in Athira Pharma (ATHA) passive or activist?
The certification states the securities were not acquired and are not held for the purpose of changing or influencing control of Athira, indicating a passive investment under Schedule 13G.
Which entities are listed as reporting persons in this Athira Pharma (ATHA) Schedule 13G/A?
The reporting persons are Acorn Bioventures, L.P., Acorn Capital Advisors GP, LLC, Acorn Bioventures 2, L.P., Acorn Capital Advisors GP 2, LLC, and Anders Hove.
What voting and dispositive powers over Athira Pharma (ATHA) shares are reported?
For each reporting person, the cover pages indicate 0 shares with sole voting or dispositive power and shared voting and dispositive power over the reported Athira common shares.
